Invention
The invention consists of novel compounds for angiogenesis-targeted therapy and imaging particularly for diseases such as cancer where increased angiogenesis is deleterious. The compounds target the VEGF receptor (VEGFR) with 100-fold improvement in binding affinity, higher specificity and tumor cell uptake and improved blood clearance. The compounds can be used to improve the targeting of imaging agents and therapeutic agents to tumor cells.

Background
Angiogenesis is a critical component for growth and metastatic spread of tumors and one of the most important regulators of angiogenesis is VEGFR. Binding of VEGF to VEGFR induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and is associated with advanced tumor growth and induction of tumor angiogenesis. Numerous drugs are in development to target the VEGF signaling pathway with a wide variability in the patient response to treatment being observed in clinical trials. Imaging agents that can determine VEGFR expression levels and identify patients that are most likely to respond to these anti-angiogenic drugs would be extremely useful. The imaging agents developed to date have had limited success due to slow clearance from blood, high uptake in non-targeted tissues such as kidney, and poor extravasations and diffusion into the extracellular space resulting in high background. There is a need for better imaging agents targeted to the VEGFR and the targeting agents may also improve the delivery of therapeutic agents to tumors.

Advantages
- The multivalent ligands are more potent binding agents for the VEGFR and increase tumor cell uptake of the imaging agents or therapeutics attached to them.
- The multivalent ligands are small molecules and so have faster, more specific binding to tumor cells than traditional large antibody constructs.
- The multivalent ligands are cleared from the blood pool faster than antibodies and are more stable so there is less non-specific background and better imaging.
- The multivalent small molecule ligands are easier to radiolabel and purify than larger antibody–based imaging agents.

For more information, contact the Office of Technology Transfer by e-mail at OTT@HoustonMethodist.org.

About Houston Methodist
Houston Methodist is comprised of a leading academic medical center in the Texas Medical Center® and four community hospitals serving the greater Houston area. Houston Methodist Hospital, the system’s flagship, is consistently listed among U.S. News & World Report’s best hospitals and we extend that same level of quality care across the system. Houston Methodist Research Institute is home to some of the world’s brightest physician-scientists, working in a collaborative environment on more than 700 clinical trials. The Research Institute is making strides in the new 440,000-square-foot facility, bringing us even closer to medical breakthroughs in cardiovascular disease, cancer, infectious disease, neurosciences, diabetes and more.

No warranty: This summary is intended for marketing purposes only, however Houston Methodist does not warrant its accuracy or completeness for that purpose or any other, and Houston Methodist specifically disclaims all warranties, whether express or implied by law, including any warranty of fitness for particular purpose and any warranty of noninfringement.